Atrium Therapeutics, Inc.
RNA
Rank in Stocks
#18140
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to... Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
Share Price
$8.38
Last synced: 2026-11-09
Market Cap
$143.35M
Change (1 day)
0.48%
Change (1 year)
-
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Atrium Therapeutics, Inc. (RNA)
Category
Healthcare
Operating Margin for Atrium Therapeutics, Inc. (RNA)
Operating Margin as of November 2026 TTM: -410.23%
According to Atrium Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is -410.23%. At the end of 2025 the company had an operating margin of -412.58%.
Operating Margin history for Atrium Therapeutics, Inc. from 2018 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -410.23% | -0.57% |
| 2025 | -412.58% | -88.14% |
| 2024 | -3,477.43% | 41.11% |
| 2023 | -2,464.41% | 27.05% |
| 2022 | -1,939.65% | 53.23% |
| 2021 | -1,265.83% | 94.03% |
| 2020 | -652.38% | -12.71% |
| 2019 | -747.39% | -73.02% |
| 2018 | -2,769.92% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.09% |
US
|
|
| -149.01% | -99.64% |
US
|
|
| 25.57% | -100.06% |
AU
|
|
| 31.23% | -100.08% |
BE
|
|
| 29.35% | -100.07% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Atrium Therapeutics, Inc.'s operating margin
What is Atrium Therapeutics, Inc.'s operating margin?
Atrium Therapeutics, Inc.'s operating margin is -410.23%, as of Nov 2026.
What was Atrium Therapeutics, Inc.'s operating margin in 2025?
In 2025, Atrium Therapeutics, Inc.'s operating margin was -412.58%, compared with -3,477.43% in 2024.
How has Atrium Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Atrium Therapeutics, Inc.'s operating margin was highest in 2025 (-412.58%) and lowest in 2024 (-3,477.43%).
How does Atrium Therapeutics, Inc.'s operating margin compare with similar companies?
Atrium Therapeutics, Inc.'s operating margin (-410.23%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.